M&A drives first-half gains
RTW Biotech Opportunities (LSE:RTW), the FTSE 250 Investment company managed by New York-based RTW Investments, has been one of the clearest beneficiaries of a recovery in biotech deal-making. In its half-year report, published on 14 September, the company said NAV per share rose 16.5% to $2.86 in the six months to 30 June. The share price rose 12.0% to $2.42.
Takeovers were the main driver. Five listed holdings received bids during the half, at premiums ranging from 19% to 163%. Apellis drew the largest premium, followed by Centessa, RAPT, Apogee, where AbbVie agreed a $10.9bn deal, and Penumbra. The largest single contributor was Kailera Therapeutics, whose stock market debut added 3.8% to NAV. Its shares closed about 62.5% above the Offer Price on the first day of trading.
Activity continued through the summer. In August, BioMarin agreed to buy private holding Alesta Therapeutics' lead asset in a deal worth up to $490m. The upfront payment implied an uplift of about 41% on RTW's carrying value and added about 0.2% to NAV. On 11 September RTW invested a further $4.1m in Encoded Therapeutics as part of a $275m Series F round to fund late-stage studies of a gene therapy for Dravet syndrome. RTW investment chief Rod Wong described it as one of the largest private financings of a central nervous system gene therapy company in recent years.
NAV, discount and buybacks
The latest monthly valuation put NAV at $2.92 per share at 31 August, up 3.9% on the month. That was behind the Nasdaq Biotech index, up 10.5%, and the Russell 2000 Biotech index, up 7.4%, in a month the company described as solid for the sector. The discount was 15.4% at the end of June, up from 12.0% at the end of 2025, though it has narrowed considerably over a longer period, from 28.9% to 13.8% in the twelve months to August.
The board has continued to buy back shares, repurchasing 7.6 million shares for $14.7m in the twelve months to August, with frequent purchases in September. In August the company appointed an additional joint corporate broker to widen its reach among investors. RTW does not pay a Dividend and reinvests returns instead.
Portfolio and outlook
At 30 June the ten largest holdings included CG Oncology at 7.2% of NAV, UroGen at 6.8%, Kailera at 5.9%, and Oruka and argenx at 5.5% each, followed by Tango, private holding Corxel, Stoke, Celcuity and Spyre. Listed companies made up 86.2% of NAV and private companies 17.8%, with the total above 100% because Leverage stood at about 1.2 times on a commitment basis.
This mix is a deliberate part of the strategy. RTW Investments, led by Rod Wong, combines investments in listed companies with private stakes in businesses it expects to list or be acquired. The aim is to capture the rise in value as companies move from private funding rounds to public markets. The Kailera listing this year is the clearest recent example of that approach working.
The manager has said it is constructive on biotechnology, citing improving sentiment, active M&A, a more supportive regulatory environment and a solid cycle of innovation. Large drugmakers facing Patent expiries need to buy new products, and that remains a key support. The sector, however, is still sensitive to interest-rate expectations, US drug-pricing policy and trial setbacks. The September NAV update, due in mid-October, will show whether the summer's gains have held.






Please wait processing your request...